Cargando…
RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates
The pandemic of COVID-19 caused by SARS-CoV-2 has raised a new challenges to the scientific and industrious fields after over 1-year spread across different countries. The ultimate approach to end the pandemic is the timely application of vaccines to achieve herd immunity. Here, a novel SARS-CoV-2 r...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423076/ https://www.ncbi.nlm.nih.gov/pubmed/34493710 http://dx.doi.org/10.1038/s41421-021-00320-y |
_version_ | 1783749393243963392 |
---|---|
author | Pan, Xiaoyan Shi, Jian Hu, Xue Wu, Yan Zeng, Liang Yao, Yanfeng Shang, Weijuan Liu, Kunpeng Gao, Ge Guo, Weiwei Peng, Yun Chen, Shaohong Gao, Xiaoxiao Peng, Cheng Rao, Juhong Zhao, Jiaxuan Gong, Cheng Zhou, Hui Lu, Yudong Wang, Zili Hu, Xiliang Cong, WenJuan Fang, Lijuan Yan, Yongxiang Zhang, Jing Xiong, Hui Yi, Jizu Yuan, Zhiming Zhou, Pengfei Shan, Chao Xiao, Gengfu |
author_facet | Pan, Xiaoyan Shi, Jian Hu, Xue Wu, Yan Zeng, Liang Yao, Yanfeng Shang, Weijuan Liu, Kunpeng Gao, Ge Guo, Weiwei Peng, Yun Chen, Shaohong Gao, Xiaoxiao Peng, Cheng Rao, Juhong Zhao, Jiaxuan Gong, Cheng Zhou, Hui Lu, Yudong Wang, Zili Hu, Xiliang Cong, WenJuan Fang, Lijuan Yan, Yongxiang Zhang, Jing Xiong, Hui Yi, Jizu Yuan, Zhiming Zhou, Pengfei Shan, Chao Xiao, Gengfu |
author_sort | Pan, Xiaoyan |
collection | PubMed |
description | The pandemic of COVID-19 caused by SARS-CoV-2 has raised a new challenges to the scientific and industrious fields after over 1-year spread across different countries. The ultimate approach to end the pandemic is the timely application of vaccines to achieve herd immunity. Here, a novel SARS-CoV-2 receptor-binding domain (RBD) homodimer was developed as a SARS-CoV-2 vaccine candidate. Formulated with aluminum adjuvant, RBD dimer elicited strong immune response in both rodents and non-human primates, and protected mice from SARS-CoV-2 challenge with significantly reducing viral load and alleviating pathological injury in the lung. In the non-human primates, the vaccine could prevent majority of the animals from SARS-CoV-2 infection in the respiratory tract and reduce lung damage. In addition, antibodies elicited by this vaccine candidate showed cross-neutralization activities to SARS-CoV-2 variants. Furthermore, with our expression system, we provided a high-yield RBD homodimer vaccine without additional biosafety or special transport device supports. Thus, it may serve as a safe, effective, and low-cost SARS-CoV-2 vaccine candidate. |
format | Online Article Text |
id | pubmed-8423076 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-84230762021-09-08 RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates Pan, Xiaoyan Shi, Jian Hu, Xue Wu, Yan Zeng, Liang Yao, Yanfeng Shang, Weijuan Liu, Kunpeng Gao, Ge Guo, Weiwei Peng, Yun Chen, Shaohong Gao, Xiaoxiao Peng, Cheng Rao, Juhong Zhao, Jiaxuan Gong, Cheng Zhou, Hui Lu, Yudong Wang, Zili Hu, Xiliang Cong, WenJuan Fang, Lijuan Yan, Yongxiang Zhang, Jing Xiong, Hui Yi, Jizu Yuan, Zhiming Zhou, Pengfei Shan, Chao Xiao, Gengfu Cell Discov Article The pandemic of COVID-19 caused by SARS-CoV-2 has raised a new challenges to the scientific and industrious fields after over 1-year spread across different countries. The ultimate approach to end the pandemic is the timely application of vaccines to achieve herd immunity. Here, a novel SARS-CoV-2 receptor-binding domain (RBD) homodimer was developed as a SARS-CoV-2 vaccine candidate. Formulated with aluminum adjuvant, RBD dimer elicited strong immune response in both rodents and non-human primates, and protected mice from SARS-CoV-2 challenge with significantly reducing viral load and alleviating pathological injury in the lung. In the non-human primates, the vaccine could prevent majority of the animals from SARS-CoV-2 infection in the respiratory tract and reduce lung damage. In addition, antibodies elicited by this vaccine candidate showed cross-neutralization activities to SARS-CoV-2 variants. Furthermore, with our expression system, we provided a high-yield RBD homodimer vaccine without additional biosafety or special transport device supports. Thus, it may serve as a safe, effective, and low-cost SARS-CoV-2 vaccine candidate. Springer Singapore 2021-09-07 /pmc/articles/PMC8423076/ /pubmed/34493710 http://dx.doi.org/10.1038/s41421-021-00320-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Pan, Xiaoyan Shi, Jian Hu, Xue Wu, Yan Zeng, Liang Yao, Yanfeng Shang, Weijuan Liu, Kunpeng Gao, Ge Guo, Weiwei Peng, Yun Chen, Shaohong Gao, Xiaoxiao Peng, Cheng Rao, Juhong Zhao, Jiaxuan Gong, Cheng Zhou, Hui Lu, Yudong Wang, Zili Hu, Xiliang Cong, WenJuan Fang, Lijuan Yan, Yongxiang Zhang, Jing Xiong, Hui Yi, Jizu Yuan, Zhiming Zhou, Pengfei Shan, Chao Xiao, Gengfu RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates |
title | RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates |
title_full | RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates |
title_fullStr | RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates |
title_full_unstemmed | RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates |
title_short | RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates |
title_sort | rbd-homodimer, a covid-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423076/ https://www.ncbi.nlm.nih.gov/pubmed/34493710 http://dx.doi.org/10.1038/s41421-021-00320-y |
work_keys_str_mv | AT panxiaoyan rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT shijian rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT huxue rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT wuyan rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT zengliang rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT yaoyanfeng rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT shangweijuan rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT liukunpeng rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT gaoge rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT guoweiwei rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT pengyun rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT chenshaohong rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT gaoxiaoxiao rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT pengcheng rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT raojuhong rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT zhaojiaxuan rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT gongcheng rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT zhouhui rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT luyudong rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT wangzili rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT huxiliang rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT congwenjuan rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT fanglijuan rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT yanyongxiang rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT zhangjing rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT xionghui rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT yijizu rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT yuanzhiming rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT zhoupengfei rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT shanchao rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates AT xiaogengfu rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates |